至今,GenScript的服务及产品已被Cell, Nature, Science, PNAS等1300多家生物医药类杂志引用近万次,处于行业领先水平。NIH、哈佛、耶鲁、斯坦福、普林斯顿、杜克大学等约400家全球著名机构使用GenScript的基因合成、多肽服务、抗体服务和蛋白服务等成功地发表科研成果,再次证明GenScript 有能力帮助业内科学家Make research easy.

MERTK mediates intrinsic and adaptive resistance to AXL-targeting agents.

Mol. Cancer Ther.. 2018-08; 
McDanielNellie K,CummingsChristopher T,IidaMari,HulseJustus,PearsonHannah E,VasileiadiEleana,ParkerRebecca E,OrbuchRachel A,OndracekOlivia J,WelkeNoah B,KangGrace H,DaviesKurtis D,WangXiaodong,FryeStephen V,EarpH Shelton,HarariPaul M,KimpleRandall J,DeRyckereDeborah,GrahamDouglas K,WheelerDer
Products/Services Used Details Operation
ORF cDNA Clones/MolecularCloud … 23900) and subcloned into the BamHI/NOTI restriction sites of the pcDNA6.0 expression vector (Life Technologies). pcDNA3.1-TYRO3 was purchased from GenScript USA Inc. (#OHu23055D, Piscataway, NJ, USA). Transfection was performed using Lipofectamine … Get A Quote

摘要

The TAM (TYRO-3, AXL, MERTK) family receptor tyrosine kinases (RTKs) play an important role in promoting growth, survival, and metastatic spread of several tumor types. AXL and MERTK are overexpressed in head and neck squamous cell carcinoma (HNSCC), triple-negative breast cancer (TNBC), and non-small cell lung cancer (NSCLC), malignancies that are highly metastatic and lethal. AXL is the most well-characterized TAM receptor and mediates resistance to both conventional and targeted cancer therapies. Since AXL is highly expressed in aggressive tumor types, cancer patients are currently being enrolled in clinical trials testing AXL inhibitors. In the current study, we analyzed the effects of AXL... More

关键词